Monitoring neuromyelitis optica activity

References

• Wildemann B, Jarius S. The expanding range of autoimmune disorders of the nervous system. Lancet Neurol. 12(1), 22–24 (2013).
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 6(9), 805–815 (2007).
   PubMed Web of Science ®Google Scholar
• Chanson JB, de Seze J, Eliaou JF, Vincent T. Immunological follow-up of patients with neuromyelitis optica: Is there a good biomarker? Lupus 22(3), 229–232 (2013).
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53(5), 1107–1114 (1999).
   PubMed Web of Science ®Google Scholar
• Merle H, Olindo S, Jeannin S et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch. Ophthalmol. 130(7), 858–862 (2012).
   PubMedGoogle Scholar
• O’Riordan JI, Gallagher HL, Thompson AJ et al. Clinical, CSF, and MRI findings in Devic’s neuromyelitis optica. J. Neurol. Neurosurg. Psychiatry 60(4), 382–387 (1996).
   PubMed Web of Science ®Google Scholar
• Takahashi T, Miyazawa I, Misu T et al. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J. Neurol. Neurosurg. Psychiatry 79(9), 1075–1078 (2008).
   PubMed Web of Science ®Google Scholar
• Hoorbakht H, Bagherkashi F. Optic neuritis, its differential diagnosis and management. Open Ophthalmol. J. 6, 65–72 (2012).
   PubMedGoogle Scholar
• Pandit L, Shetty R, Misri Z et al. Optic neuritis: experience from a south Indian demyelinating disease registry. Neurol. India 60(5), 470–475 (2012).
   PubMed Web of Science ®Google Scholar
• Merle H, Olindo S, Bonnan M et al. Natural history of the visual impairment of relapsing neuromyelitis optica. Ophthalmology 114(4), 810–815 (2007).
   PubMed Web of Science ®Google Scholar
• Papais-Alvarenga RM, Miranda-Santos CM, Puccioni-Sohler M et al. Optic neuromyelitis syndrome in Brazilian patients. J. Neurol. Neurosurg. Psychiatry 73(4), 429–435 (2002).
   PubMed Web of Science ®Google Scholar
• Morrow MJ, Wingerchuk D. Neuromyelitis optica. J. Neuroophthalmol. 32(2), 154–166 (2012).
   PubMed Web of Science ®Google Scholar
• de Seze J, Stojkovic T, Ferriby D et al. Devic’s neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J. Neurol. Sci. 197(1–2), 57–61 (2002).
   PubMed Web of Science ®Google Scholar
• Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch. Neurol. 63(3), 390–396 (2006).
   PubMedGoogle Scholar
• Ito S, Mori M, Makino T, Hayakawa S, Kuwabara S. ‘Cloud-like enhancement’ is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann. Neurol. 66(3), 425–428 (2009).
   PubMed Web of Science ®Google Scholar
• Johnson G, Miller DH, MacManus D et al. STIR sequences in NMR imaging of the optic nerve. Neuroradiology 29(3), 238–245 (1987).
   PubMed Web of Science ®Google Scholar
• Kupersmith MJ, Alban T, Zeiffer B, Lefton D. Contrast-enhanced MRI in acute optic neuritis: relationship to visual performance. Brain 125( Pt 4), 812–822 (2002).
   PubMed Web of Science ®Google Scholar
• Khanna S, Sharma A, Huecker J, Gordon M, Naismith RT, van Stavern GP. Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J. Neuroophthalmol. 32(3), 216–220 (2012).
   PubMed Web of Science ®Google Scholar
• Krampla W, Aboul-Enein F, Jecel J et al. Spinal cord lesions in patients with neuromyelitis optica: a retrospective long-term MRI follow-up study. Eur. Radiol. 19(10), 2535–2543 (2009).
   PubMed Web of Science ®Google Scholar
• Sellner J, Boggild M, Clanet M et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur. J. Neurol. 17(8), 1019–1032 (2010).
   PubMed Web of Science ®Google Scholar
• Ratelade J, Verkman AS. Neuromyelitis optica: aquaporin-4 based pathogenesis mechanisms and new therapies. Int. J. Biochem. Cell Biol. 44(9), 1519–1530 (2012).
   PubMed Web of Science ®Google Scholar
• Papadopoulos MC, Verkman AS. Aquaporin 4 and neuromyelitis optica. Lancet Neurol. 11(6), 535–544 (2012).
   PubMed Web of Science ®Google Scholar
• Petzold A, de Boer JF, Schippling S et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 9(9), 921–932 (2010).
   PubMed Web of Science ®Google Scholar
• Noval S, Contreras I, Muñoz S, Oreja-Guevara C, Manzano B, Rebolleda G. Optical coherence tomography in multiple sclerosis and neuromyelitis optica: an update. Mult. Scler. Int. 11 (2011).
   Google Scholar
• Nakamura M, Nakazawa T, Doi H et al. Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber layer thickness in patients with neuromyelitis optica. Graefes Arch. Clin. Exp. Ophthalmol. 248(12), 1777–1185 (2010).
   PubMed Web of Science ®Google Scholar
• Naismith RT, Tutlam NT, Xu J et al. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology 72(12), 1077–1082 (2009).
   PubMed Web of Science ®Google Scholar
• Merle H, Olindo S, Donnio A, Richer R, Smadja D, Cabre P. Retinal peripapillary nerve fiber layer thickness in neuromyelitis optica. Invest. Ophthalmol. Vis. Sci. 49(10) 4412–4417 (2008).
   PubMed Web of Science ®Google Scholar
• Monteiro MLR, Fernandes DB, Apóstolos-Pereira SL, Callegaro D. Quantification of retinal neural loss in patients with neuromyelitis optica and multiple sclerosis with or without optic neuritis using Fourier-domain optical coherence tomography. Invest. Ophthalmol. Vis. Sci. 53(7), 3959–3966 (2012).
   PubMed Web of Science ®Google Scholar
• Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch. Neurol. 69(9), 1176–1180 (2012).
   PubMedGoogle Scholar
• Fernandes DB, Raza AS, Nogueira RGF et al. Evaluation of inner retinal layers in patients with multiple sclerosis or neuromyelitis optica using optical coherence tomography. Ophthalmology 120(2), 387–394 (2013).
   PubMed Web of Science ®Google Scholar
• Ratchford JN, Quigg ME, Conger A et al. Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 73(4), 302–308 (2009).
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Nolan R, Schwartz DM, Graves J, Green AJ. Microcystic macular oedema in multiple sclerosis is associated with disease severity. Brain 135( Pt 6), 1786–1793 (2012).
   PubMed Web of Science ®Google Scholar
• Saidha S, Sotirchos ES, Ibrahim MA et al. Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol. 11(11), 963–972 (2012).
   PubMed Web of Science ®Google Scholar
• Sotirchos ES, Saidha S, Byraiah G et al. In vivo identification of morphologic retinal abnormalities in neuromyelitis optica. Neurology 80(15), 1406–1414 (2013).
   PubMed Web of Science ®Google Scholar
• Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat. Rev. Neurol. 6(7), 383–392 (2010).
   PubMed Web of Science ®Google Scholar
• Llufriu S, Castillo J, Blanco Y et al. Plasma exchange for acute attacks of CNS demyelination: predictors of improvement at 6 months. Neurology 73(12), 949–953 (2009).
   PubMed Web of Science ®Google Scholar
• Watanabe S, Nakashima I, Misu T et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult. Scler. 13(1), 128–132 (2007).
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, O’Brien PC, Petterson TM et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann. Neurol. 46(6), 878–886 (1999).
   PubMed Web of Science ®Google Scholar
• Nicchia GP, Nico B, Camassa LMA et al. The role of aquaporin-4 in the blood-brain barrier development and integrity: studies in animal and cell culture models. Neuroscience 129(4), 935–945 (2004).
   PubMed Web of Science ®Google Scholar
• Palace J, Leite MI, Nairne A, Vincent A. Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch. Neurol. 67(8), 1016–1017 (2010).
   PubMedGoogle Scholar
• Warabi Y, Matsumoto Y, Hayashi H. Interferon beta-1b exacerbates multiple sclerosis with severe optic nerve and spinal cord demyelination. J. Neurol. Sci. 252(1), 57–61 (2007).
   PubMed Web of Science ®Google Scholar
• Okamoto T, Ogawa M, Lin Y, Murata M, Miyake S, Yamamura T. Treatment of neuromyelitis optica: current debate. Ther. Adv. Neurol. Disord. 1(1), 5–12 (2008).
   PubMedGoogle Scholar
• Cree B. Neuromyelitis optica: diagnosis, pathogenesis, and treatment. Curr. Neurol. Neurosci. Rep. 8(5), 427–433 (2008).
   PubMed Web of Science ®Google Scholar
• Jacob A, Weinshenker BG, Violich I et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch. Neurol. 65(11), 1443–1448 (2008).
   PubMed Web of Science ®Google Scholar
• Cree BAC, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64(7), 1270–1272 (2005).
   PubMed Web of Science ®Google Scholar
• Kim S-H, Kim W, Li XF, Jung I-J, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch. Neurol. 68(11), 1412–1420 (2011).
   PubMedGoogle Scholar
• Nakashima I, Takahashi T, Cree BAC et al. Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J. Clin. Neurosci. 18(7), 997–998 (2011).
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim W, Park MS, Sohn EH, Li XF, Kim HJ. Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica. Arch. Neurol. 68(4), 473–479 (2011).
   PubMedGoogle Scholar
• González C, González-Buitrago JM, Izquierdo G. Aquaporins, anti-aquaporin-4 autoantibodies and neuromyelitis optica. Clin. Chim. Acta 415, 350–360 (2013).
   PubMed Web of Science ®Google Scholar
• Tradtrantip L, Zhang H, Anderson MO et al. Small-molecule inhibitors of NMO-IgG binding to aquaporin-4 reduce astrocyte cytotoxicity in neuromyelitis optica. FASEB J. 26(5), 2197–2208 (2012).
   PubMed Web of Science ®Google Scholar
• Uzawa A, Mori M, Arai K et al. Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6. Mult. Scler. 16(12), 1443–1452 (2010).
   PubMed Web of Science ®Google Scholar
• Chihara N, Aranami T, Sato W et al. Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. Proc. Natl Acad. Sci. U. S. A. 108(9), 3701–3706 (2011).
   PubMed Web of Science ®Google Scholar
• Ayzenberg I, Kleiter I, Schröder A et al. Interleukin 6 Receptor Blockade in Patients With Neuromyelitis Optica Nonresponsive to Anti-CD20 Therapy. JAMA Neurol. 70(3), 394–397 (2013).
   PubMed Web of Science ®Google Scholar
• Herges K, de Jong BA, Kolkowitz I et al. Protective effect of an elastase inhibitor in a neuromyelitis optica-like disease driven by a peptide of myelin oligodendroglial glycoprotein. Mult. scler. 18(4), 398–408 (2012).
   PubMed Web of Science ®Google Scholar
• Saadoun S, Waters P, MacDonald C et al. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann. Neurol. 71(3), 323–333 (2012).
   PubMed Web of Science ®Google Scholar
• Kieseier BC, Stüve O, Dehmel T et al. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. JAMA Neurol. 70(3), 390–393 (2013).
   PubMed Web of Science ®Google Scholar
• Wang KC, Tsai CP, Lee CL, Chen SY, Chin LT, Chen SJ. Elevated plasma high-mobility group box 1 protein is a potential marker for neuromyelitis optica. Neuroscience 226, 510–516 (2012).
   PubMed Web of Science ®Google Scholar
• Kageyama T, Komori M, Miyamoto K et al. Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J. Neurol. 260(2), 627–634 (2013).
   PubMed Web of Science ®Google Scholar
• Liu C, Xu Y, Cui L et al. Serum uric acid levels and their correlation with clinical and cerebrospinal fluid parameters in patients with neuromyelitis optica. J. Clin. Neurosci. 20(2), 278–280 (2013).
   PubMed Web of Science ®Google Scholar
• Jarius S, Aboul-Enein F, Waters P et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 131( Pt 11), 3072–3080 (2008).
   PubMed Web of Science ®Google Scholar
• Xu Y, Zhang Y, Liu C et al. Serum antibodies to 25 myelin oligodendrocyte glycoprotein epitopes in multiple sclerosis and neuromyelitis optica: clinical value for diagnosis and disease activity. Chin. Med. J. 125(18), 3207–3210 (2012).
   PubMed Web of Science ®Google Scholar
• Min JH, Waters P, Vincent A et al. Reduced serum uric acid levels in neuromyelitis optica: serum uric acid levels are reduced during relapses in NMO. Acta Neurol. Scand. 126(4), 287–291 (2012).
   PubMed Web of Science ®Google Scholar
• Wu A, Zhong X, Wang H et al. Cerebrospinal fluid IL-21 levels in Neuromyelitis Optica and multiple sclerosis. Can. J. Neurol. Sci. 39(6), 813–820 (2012).
   PubMed Web of Science ®Google Scholar
• Feng X, Reder NP, Yanamandala M et al. Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. J. Neurol. Sci. 313(1–2), 48–53 (2012).
   PubMed Web of Science ®Google Scholar
• Wang H, Wang K, Zhong X et al. Plasma sCD28, sCTLA-4 levels in neuromyelitis optica and multiple sclerosis during relapse. J. Neuroimmunol. 243(1–2), 52–55 (2012).
   PubMed Web of Science ®Google Scholar
• Wang H, Wang K, Zhong X et al. Notable increased cerebrospinal fluid levels of soluble interleukin-6 receptors in neuromyelitis optica. Neuroimmunomodulation 19(5), 304–308 (2012).
   PubMed Web of Science ®Google Scholar
• Wang H, Wang K, Wang C et al. Cerebrospinal fluid high-mobility group box protein 1 in neuromyelitis optica and multiple sclerosis. Neuroimmunomodulation 20(2), 113–118 (2013).
   PubMed Web of Science ®Google Scholar
• Wang H, Wang K, Zhong X et al. Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse. J. Clin. Immunol. 32(5), 1007–1011 (2012).
   PubMed Web of Science ®Google Scholar
• Zhong X, Wang H, Dai Y et al. Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica. J. Neuroimmunol. 240(241), 104–108 (2011).
   PubMedGoogle Scholar
• Ketelslegers IA, Catsman-Berrevoets CE, Neuteboom RF et al. Incidence of acquired demyelinating syndromes of the CNS in Dutch children: a nationwide study. J. Neurol. 259(9), 1929–1935 (2012).
   PubMed Web of Science ®Google Scholar
• Huppke P, Bluthner M, Bauer O et al. Neuromyelitis optica and NMO-IgG in European pediatric patients. Neurology 75(19), 1740–1744 (2010).
   PubMed Web of Science ®Google Scholar
• Qiu HY, Wei SH. Clinical analysis of the etiology of optic neuritis in patients at different ages in china. Yan Ke Xue Bao 27(2), 98–101 (2012).
   PubMedGoogle Scholar
• Lotze TE, Northrop JL, Hutton GJ, Ross B, Schiffman JS, Hunter JV. Spectrum of pediatric neuromyelitis optica. Pediatrics 122(5), e1039–e1047 (2008).
   PubMed Web of Science ®Google Scholar
• Collongues N, Marignier R, Zéphir H et al. Neuromyelitis optica in France: a multicenter study of 125 patients. Neurology 74(9), 736–742 (2010).
   PubMed Web of Science ®Google Scholar
• Wei W, Zerfoss E, Ashker L, Cantore WA. Bilateral optic neuritis in pediatric systemic lupus erythematosus associated with antiphospholipid antibodies and neuromyelitis optica immunoglobulin. J. Pediatr. Ophthalmol. Strabismus. 47, e1–e4 (2010).
   Google Scholar
• Tillema JM, McKeon A. The spectrum of neuromyelitis optica (NMO) in childhood. J. Child Neurol. 27(11), 1437–1447 (2012).
   PubMed Web of Science ®Google Scholar
• Sri-udomkajorn S, Pongwatcharaporn K. Clinical features and outcome of childhood optic neuritis at Queen Sirikit National Institute of Child Health. J. Med. Assoc. Thai. 94(Suppl. 3), S189–S194 (2011).
   Google Scholar
• Peña JA, Ravelo ME, Mora-La Cruz E, Montiel-Nava C. NMO in pediatric patients: brain involvement and clinical expression. Arq. Neuropsiquiatr. 69(1), 34–38 (2011).
   PubMed Web of Science ®Google Scholar
• Collongues N, Marignier R, Zéphir H et al. Long-term follow-up of neuromyelitis optica with a pediatric onset. Neurology 75(12), 1084–1088 (2010).
   PubMed Web of Science ®Google Scholar
• Yavuz H, Kiresi D. Unusual manifestations of pediatric neuromyelitis optica. J. Child Neurol. 28(5), 658–662 (2013).
   PubMed Web of Science ®Google Scholar
• Krupp LB, Banwell B, Tenembaum S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 68(16 Suppl. 2), S7–S12 (2007).
   Google Scholar
• Rostásy K, Mader S, Hennes E et al. Persisting myelin oligodendrocyte glycoprotein antibodies in aquaporin-4 antibody negative pediatric neuromyelitis optica. Mult. Scler. 19(8), 1052–1059 (2013).
   PubMed Web of Science ®Google Scholar
• Lim BC, Hwang H, Kim KJ et al. Relapsing demyelinating CNS disease in a Korean pediatric population: multiple sclerosis versus neuromyelitis optica. Mult. Scler. 17(1), 67–73 (2011).
   PubMed Web of Science ®Google Scholar
• Bonhomme GR, Mitchell EB. Treatment of pediatric optic neuritis. Curr. Treat. Options Neurol. 14(1), 93–102 (2012).
   PubMed Web of Science ®Google Scholar
• Fukui M, Shimakawa S, Ashida A, Takahashi T, Tamai H. [Successful plasma exchange treatment for a case with neuromyelitis optica]. No To Hattatsu 43(5), 389–393 (2011).
   PubMedGoogle Scholar
• Mahmood NA, Silver K, Onel K, Ko M, Javed A. Efficacy and safety of rituximab in pediatric neuromyelitis optica. J. Child Neurol. 26(2), 244–247 (2011).
   PubMed Web of Science ®Google Scholar
• Pittock SJ, McKeon A, Mandrekar JN et al. Pilot trial of eculizumab in AQP4-IgG-positive NMO. Ann. Neurol. 72(Suppl. 16), S116 (2012).
   Google Scholar